Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPN | P05981 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.49 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14116233 | 0.88 | SIGMAR1 (0.43) | CHRM2CHRM3CYP2D6CYP2C9F10 | |
| SCHEMBL14116439 | 0.88 | SIGMAR1 (0.43) | CHRM2CHRM3CYP2D6CYP2C9F10 | |
| SCHEMBL1850544 | 0.84 | CYP2D6 (0.63) | CHRM2CHRM3CYP2D6CYP2C9OPRM1 | |
| SCHEMBL23297070 | 0.84 | ACHE (0.59) | CHRM2CHRM3CYP2D6CYP2C9DRD2 | |
| SCHEMBL23296694 | 0.76 | CHRM3 (0.53) | CHRM2CHRM3DRD2DRD4DRD3 | |
| SCHEMBL23296831 | 0.76 | CHRM3 (0.53) | CHRM2CHRM3DRD2DRD4DRD3 | |
| SCHEMBL4585565 | 0.76 | LTA4H (0.60) | CHRM2CHRM3CYP2D6CYP2C9DRD2 | |
| SCHEMBL23296895 | 0.76 | CHRM2 (0.54) | CHRM2CHRM3DRD2DRD4DRD3 | |
| SCHEMBL16996639 | 0.76 | TACR1 (0.51) | CHRM2CHRM3ALDH1A1 | |
| SCHEMBL266138 | 0.76 | NPC1 (0.71) | DRD2DRD4DRD3ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100591679-C | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV | 2010-02-24 | — | — | CN | disclosed |
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | disclosed |
| CN-1860117-A | Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-08 | — | — | CN | disclosed |
| CN-1856490-A | Benzimidazole, benzothiazole and benzoxazole derivatives and their use as LTA4H modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | LTA4H, LTC4S, LTB4R | CHRM2 2695/4885CHRM3 2043/4885CYP2D6 926/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | CHRM2 1089/4885CHRM3 952/4885CYP2D6 2071/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | CHRM2 2989/4885CHRM3 1821/4885CYP2D6 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.